Answer
After binding to HER2, trastuzumab emtansine undergoes receptor-mediated internalisation followed by lysosomal degradation, releasing DM1-containing cytotoxic catabolites, primarily lysine-MCC-DM1, inside tumour cells.
Sources for this answer
- Kadcyla 100 mg and 160 mg Powder for Concentrate for Solution for InfusionRoche Products Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 20Document updated
Sources checked